ZBH vs. STE, ALGN, SNN, EW, PHG, CAH, WST, ICLR, BNTX, and WAT
Should you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include STERIS (STE), Align Technology (ALGN), Smith & Nephew (SNN), Edwards Lifesciences (EW), Koninklijke Philips (PHG), Cardinal Health (CAH), West Pharmaceutical Services (WST), ICON Public (ICLR), BioNTech (BNTX), and Waters (WAT). These companies are all part of the "medical" sector.
Zimmer Biomet (NYSE:ZBH) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.8%. STERIS pays an annual dividend of $2.08 per share and has a dividend yield of 0.9%. Zimmer Biomet pays out 20.8% of its earnings in the form of a dividend. STERIS pays out 54.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Zimmer Biomet has higher revenue and earnings than STERIS. Zimmer Biomet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.
In the previous week, STERIS had 1 more articles in the media than Zimmer Biomet. MarketBeat recorded 17 mentions for STERIS and 16 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.82 beat STERIS's score of 0.77 indicating that Zimmer Biomet is being referred to more favorably in the media.
Zimmer Biomet received 566 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 68.23% of users gave Zimmer Biomet an outperform vote while only 58.51% of users gave STERIS an outperform vote.
Zimmer Biomet has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Zimmer Biomet currently has a consensus price target of $133.29, indicating a potential upside of 10.91%. STERIS has a consensus price target of $241.60, indicating a potential upside of 3.83%. Given Zimmer Biomet's higher possible upside, equities analysts plainly believe Zimmer Biomet is more favorable than STERIS.
88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by company insiders. Comparatively, 1.0% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Zimmer Biomet has a net margin of 12.93% compared to STERIS's net margin of 6.95%. STERIS's return on equity of 13.73% beat Zimmer Biomet's return on equity.
Summary
Zimmer Biomet beats STERIS on 11 of the 19 factors compared between the two stocks.
Get Zimmer Biomet News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zimmer Biomet Competitors List
Related Companies and Tools
